The New Zealand pharmaceutical management agency, PHARMAC, expects to save NZ$24 million (US$17.1 million) over the next five years following price reductions for certain antipsychotic drugs. The agency intends to use the savings to fund other medicines.
New Zealand expects big savings with generic quetiapine
Home/Policies & Legislation
|
Posted 17/09/2010
0
Post your comment

PHARMAC’s decision to fund the Dr Reddy’s brand of the antipsychotic medicine quetiapine adds a third option to the existing two brands of quetiapine: Quetapel and Seroquel.
The New Zealand reference pricing system will also cause the reimbursement price of one of the existing drugs on the market, Seroquel, to be reduced. This could cause patient co-payments to increase unless the manufacturer, AstraZeneca, decides to adjust the price.
About 34,000 people a year take quetiapine, which is used to treat schizophrenia and other psychotic illnesses and is occasionally prescribed as a sedative. PHARMAC expects any change in brands for patients taking quetiapine to be manageable.
“The savings are important to help PHARMAC manage overall pharmaceutical spending”, says PHARMAC Medical Director, Dr Peter Moodie.
Reference
PHARMAC Media Release. Funding change for mental health medicine to save $24 million. 30 August 2010.
Guidelines
Canada poised to remove requirement for Phase III trials for biosimilars
European position paper on AI in medicinal product lifecycle
Reports
Regulating biosimilars in Argentina: ANMAT’s approach
China-to-West pharma licensing deals surge in 2024 amid innovation push
DIGEMID’s 45-day auto-approvals trigger safety warning

Home/Policies & Legislation Posted 30/06/2025
ANVISA and Danish Medicines Agency renew health regulatory collaboration

Home/Policies & Legislation Posted 06/05/2025
Colombia and Brazil introduce reforms to enhance healthcare regulation

Home/Policies & Legislation Posted 22/04/2025
Second wave of drugs selected for Medicare price negotiation

Home/Policies & Legislation Posted 11/04/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment